On May 26, 2022 Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, reported that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in three upcoming investor conferences (Press release, Kura Oncology, MAY 26, 2022, View Source [SID1234615062]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A virtual fireside chat at Cowen’s 3rd Annual Oncology Innovation Summit at 3:30 p.m. ET / 12:30 p.m. PT on June 2, 2022;

A fireside chat at the Jefferies Healthcare Conference in New York at 10:30 a.m. ET / 7:30 a.m. PT on June 8, 2022; and

A fireside chat at the JMP Securities Life Sciences Conference in New York at 2:30 p.m. ET / 11:30 a.m. PT on June 16, 2022.
Audio webcasts will be available in the Investors section of Kura’s website at www.kuraoncology.com, with archived replays available following each event.